Understanding and Preventing Osteoporosis

Alendronate: RxList generic information. <http://www.rxlist.com/cgi/generic/alendron.html> (1997, May 28).

Ali N. Bennett S. (1992). Postmenopausal women: Factors in osteoporosis preventive behaviors. Journal of Gerontological Nursing, 18, 23–32.

Aloia J.F. (1989). Osteoporosis: A guide to prevention and treatment. Champaign. IL.

Avioli L. (1991). Significance of osteoporosis: A growing international health care problem. Calcified Tissue International, 49(suppl), S5–S7.

Burger C.W. Koomen I. Peters N.A. Van Leeuwen F.E. Kenemans P. (1997). Postmenopausal hormone replacement therapy and cancer of the female genital tract and the breast. European Menopause Journal. 4(1), 23–36.

Callens A. Vaillant L. Lecomte P. Berson M. Gall Y. Lorette G. (1996). Does hormonal skin aging exist? A study of the influence of different hormone therapy regimens on the skin of postmenopausal women using non-invasive measurement techniques. Dermatology, 193, 289–294.

Carr B.R. Dawson-Hughes B. Ettinger B. , (1993). A real-world approach to osteoporosis. Patient Care, 27, 31–56.

Chapuy M.C. Arlot M.E. Duboeuf F. Brun J. Crouzet B. Arnaud S. Dalmas P. Meunier P.J. (1992). Vitamin D and calcium to prevent hip fractures in elderly women. New England Journal of Medicine, 327, 82–87.

Chung P.H. Maroulis G.B. , (1996). Osteoporosis: An update on prevention and treatment. Physician Assistant, 20(4), 83–91.

Cranney A. Moher D. Shea B. Wells G. Adachi R. Tugwell P. (1995). Metaanalysis of calcitonin in the treatment of postmenopausal osteoporosis. American College of Rheumatology, 38, S360.

DeImas P.D. Garnero P. (1996), Utility of biochemical markers of bone turnover in osteoporosis (pp. 1075–1088). In: Marcus F. Feldman K.J. (Eds.). Osteoporosis (pp. 1075–1088). Academic Press.

Environmental Estrogens. (1997). <http://www.tmc.tulane.edu/cbr/ecme/EEHorne/1_WhatDoWeKnow/1_UnderstandEE/4NatHorrnThreat.html> (June 18, 1997).

Ettinger B. Friedman G. Bush T. Quesenberry C. (1996). Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstetrics & Gynecology, 87, 6–12.

Fuller J. (1996). Fannie Mae takes on osteoporosis with targeted prevention program. AWHP's Worksite Health, Summer. 20–22.

Gruber H.E. Ivey J.L. Baylink D.J. Matthews M. Nelp W.B. Sison K. Chestnut C.H. (1984). Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism, 33, 295–303.

Hulka B.S. (1990). Hormone-replacement therapy and the risk of breast cancer. Cancer, 40, 289–296.

Jacobowitz R.S. (1993). 150 most-asked questions about osteoporosis: What women really want to know. New York: Hearst Books.

Jensen J. Christiansen C. Rodbro P. (1985). Cigarette smoking, serum estrogens, and bone loss during hormone replacement therapy early after menopause. New England Journal of Medicine, 313, 973–977.

Kessenich C.R. (1996). Update on pharmacologic therapies for osteoporosis. Nurse Practitioner, 21(8), 19–24.

Laitinen K. Vlimki M. (1991). Alcohol and bone. Calcified Tissue International, 49(suppl), S70–S73.

Law M.R. Wald N.J. Meade T.W. (1991). Strategies for prevention of osteoporosis and hip fracture. British Medical Journal, 303, 453–459.

Lydick E. Turpin J. Cook K. Stine R. Byrnes C. (1996). Development and validation of a simple question to facilitate identification of women with low bone density. Journal of Bone Mineral Research, 11, M746.

Merck & Co. Inc., (1995). Osteoporosis: Building a stronger future. Boston, MA.

Martorana F.R. Broggini M. (1995). Long-term tolerability of nasal spray formulation of salmon calcitonin. Current Therapeutic Research, 56, 429–435.

Melton L. Kan S. Wahner H. Riggs L. (1988). Lifetime fracture risk: An approach to hip fracture risk assessment based on bone mineral density and age. Journal of Clinical Epidemiology, 41, 985–994.

Moussa J. Elias Y.E. Libanati C. (1997). Osteoporosis: Prevention and treatment in the primary care setting. Primary Care Reports, 3, 1–8.

National Institute of Health Consensus Panel, (1994). NIH Consensus Development Conference on Optimal Calcium Intake. Bethesda, MD: National Institutes of Health.

National Osteoporosis Foundation. (1994). Stand up to osteoporosis: Your guide to staying healthy and independent through prevention and treatment. Washington, D.C.

Non-Dairy Sources of Calcium. <http://elaine.teleport.com/∼amrta/calcium.html> (1997, May 22).

Pak Y. Sakhaee K. Adams-Huet B. Piziak V. Peterson R. Poindexter J. (1995). Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Annals of Internal Medicine, 123(6), 401–408.

PDR Generics (1995). (1st edition). Montvale, NJ: Medical Economics. Physician's Desk Reference (51st edition). (1997). Montvale, NJ: Medical Economics.

PiIerard G.E. Letawe C. Dowlati A. PiIerard-Franchimont C. (1995). Effect of hormone replacement therapy for menopause on the mechanical properties of skin. Journal of American Geriatric Society, 43, 662–665.

Riffe J.M. (1992). Osteoporosis prevention and management. American Pharmacy, 32(8), 61–70.

Riggs B.L. Melton L.J. (1988). Osteoporosis: Etiology, diagnosis, and management. New York: Raven Press.

Schlenker E.D. (1993). Nutrition in aging (2nd ed.). St. Louis: Mosby Year Book, Inc.

Sit J. Taking supplements for osteoporosis. <http://www.uop.edu/pharmacy/asp/osteoporosis/pages/supps.htm#optimal>.

Sizer F. Whitney E. (1994). Nutrition concepts and controversies. St. Paul: West Publishing Company.

Thacker H.L. (1996). Update on hormone replacement: Sorting out the options for preventing coronary artery disease and osteoporosis. Medscape Women's Health, <http://www.medscape.com/Medscape/womens.health/1996/v01.n067w26.thacker.html> (1997, May 28).

Tolstoi L.G. Levin R.M. (1992). Osteoporosis: The treatment controversy. Nutrition Today, July-August, 6–29.

Wardlaw G.M. (1993). Putting osteoporosis in perspective. Journal of the American Dietetic Association, 93(9), 1000–1006.

Woolfe A.D. Dixon A.S. (1988). Osteoporosis: A clinical guide. Philadelphia: J.B. Lippincott Company.